Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose

Table 3 Comparison of glucose control parameters, insulin secretion and sensitivity surrogates before and after treatment in both groups

	Acarbose (n = 28)			Glibenclamide (n = 23)
	Before	After	P-values vs. baseline	Before	After	P-values vs. baseline
BMI (kg/m²)	25.9 ± 3.0	25.5 ± 3.3	0.005*	25.3 ± 3.8	25.5 ± 4.0	0.072
Fasting plasma glucose (mmol/l)	8.2 ± 1.2	7.3 ± 1.2	0.002*	9.0 ± 3.0	7.2 ± 2.1	0.001*
HbA_1c (%)	8.2 ± 0.8	7.5 ± 0.8	<0.001*	8.6 ± 1.6	7.4 ± 1.2	<0.001*
HOMA-IR	3.0 ± 1.4	3.1 ± 2.9	0.682	4.8 ± 3.9	3.5 ± 2.7	0.101
HOMA-β (%)	40.3 ± 30.0	49.4 ± 40.2	0.021*	53.7 ± 50.5	47.0 ± 83.4	0.153
Insulinogenic index₃₀ (pmol/mmol)	47.9 ± 79.0	50.6 ± 42.0	0.080	35.0 ± 37.2	36.1 ± 24.5	0.191
MISI	3.6 ± 1.8	4.6 ± 2.8	0.124	3.2 ± 1.7	4.1 ± 2.9	0.176
AUC_ins₁₂₀/AUC_{glu 120}^§(pmol/mmol)	2.9 ± 2.3	3.8 ± 3.1	0.003*	2.7 ± 1.4	3.3 ± 1.7	0.121
DI₁₂₀	62.5 ± 31.4	91.7 ± 36.2	0.002*	51.2 ± 24.2	74.9 ± 41.9	0.003*

Wilcoxon signed rank test; Data are presented as mean ± standard deviation. *P <0.05: § total area under curve of insulin within 120 minutes divided by total area under curve of glucose within 120 minutes.
DI, disposition index; HOMA-β, homeostasis model assessment β-cell function index; HOMA-IR, homeostasis model assesment insulin resistance index; MISI, Matsuda insulin sensitivity index.

ISSN: 1758-5996